David W Holt

List of Publications by Year
in descending order

106 papers	4,469 citations	186265 28 h-index	168389 53 g-index
107 all docs	107 docs citations	107 times ranked	3182 citing authors

#	Article	IF	Citations
1	Amiodarone pharmacokinetics. American Heart Journal, 1983, 106, 840-847.	2.7	415
2	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. Therapeutic Drug Monitoring, 2009, 31, 139-152.	2.0	398
3	Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation. Therapeutic Drug Monitoring, 2006, 28, 145-154.	2.0	305
4	Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement. Transplantation, 2002, 74, 1486-1489.	1.0	283
5	Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 341-358.	4.5	276
6	Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion. Therapeutic Drug Monitoring, 2001, 23, 305-315.	2.0	239
7	The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation. American Journal of Transplantation, 2004, 4, 914-919.	4.7	238
8	Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. Transplantation, 2008, 86, 1043-1051.	1.0	238
9	Case series of individuals with analytically confirmed acute mephedrone toxicity. Clinical Toxicology, 2010, 48, 924-927.	1.9	192
10	Recreational Use of Mephedrone (4-Methylmethcathinone, 4-MMC) with Associated Sympathomimetic Toxicity. Journal of Medical Toxicology, 2010, 6, 327-330.	1.5	185
11	Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians. Transplantation, 2005, 79, 499-502.	1.0	178
12	Substandard drugs: a potential crisis for public health. British Journal of Clinical Pharmacology, 2014, 78, 218-243.	2.4	174
13	Therapeutic monitoring of mycophenolic acid. Clinical Biochemistry, 1998, 31, 317-322.	1.9	118
14	Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clinical Therapeutics, 1999, 21, 1632-1652.	2.5	106
15	Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring, 2016, 38, 143-169.	2.0	102
16	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice. Therapeutic Drug Monitoring, 2016, 38, 170-189.	2.0	95
17	International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring. Therapeutic Drug Monitoring, 2002, 24, 59-67.	2.0	82
18	Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). Journal of Medical Toxicology, 2008, 4, 254-257.	1.5	58

#	Article	IF	Citations
19	Monitoring mycophenolic acid. Annals of Clinical Biochemistry, 2002, 39, 173-183.	1.6	55
20	The Need for Standardization of Tacrolimus Assays. Clinical Chemistry, 2011, 57, 1739-1747.	3.2	55
21	Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Current Opinion in Nephrology and Hypertension, 2002, 11, 657-663.	2.0	51
22	Multidrug Resistance Gene-1 (MDR-1) Haplotypes Have a Minor Influence on Tacrolimus Dose Requirements. Transplantation, 2006, 82, 705-708.	1.0	50
23	Bioequivalence of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil: A Meta-Analysis of Three Studies in Stable Renal Transplant Recipients. Transplantation, 2006, 82, 1413-1418.	1.0	50
24	A Pharmacogenetic Strategy for Immunosuppression Based on the CYP3A5 Genotype. Transplantation, 2008, 85, 163-165.	1.0	49
25	Standardization of LC-MS for Therapeutic Drug Monitoring of Tacrolimus. Clinical Chemistry, 2013, 59, 1630-1637.	3.2	42
26	Myocardial Injury Induced by Radiofrequency and Low Energy Ablation: A Quantitative Study of CK Isoforms, CK-MB, and Troponin-T Concentrations. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1410-1416.	1.2	34
27	Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clinical Transplantation, 2007, 21, 252-257.	1.6	31
28	Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]). Journal of Medical Toxicology, 2008, 4, 167-169.	1.5	29
29	The Pharmacogenetics of Immunosuppression for Organ Transplantation. Molecular Diagnosis and Therapy, 2003, 3, 291-301.	3.3	28
30	Class III Antiarrhythmics in Overdose. Drug Safety, 1993, 9, 450-462.	3.2	25
31	Pharmacogenomics of immunosuppressive drug metabolism. Current Opinion in Nephrology and Hypertension, 2003, 12, 607-613.	2.0	25
32	Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. Nephrology Dialysis Transplantation, 2010, 25, 628-634.	0.7	25
33	Elevated serum levels of soluble interleukin-2 receptor, neopterin and Î²-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. European Journal of Heart Failure, 2001, 3, 155-163.	7.1	24
34	First case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicological screening. European Journal of Emergency Medicine, 2008, 15, 354-356.	1.1	23
35	How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transplant Immunology, 2002, 9, 211-214.	1.2	22
36	Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opinion on Pharmacotherapy, 2007, 8, 2045-2058.	1.8	22

#	Article	IF	Citations
37	Detection of the pharmaceutical agent glaucine as a recreational drug. European Journal of Clinical Pharmacology, 2008, 64, 553-554.	1.9	22
38	Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients. Pharmacogenomics, 2008, 9, 585-596.	1.3	22
39	Genotyping cytochrome P450 3A5 using the Light Cycler. Annals of Clinical Biochemistry, 2005, 42, 376-381.	1.6	19
40	Cyclosporine monitoring based on C2 sampling. Transplantation, 2002, 73, 840-841.	1.0	12
41	A herbal treatment for type 2 diabetes adulterated with undisclosed drugs. Lancet, The, 2018, 391, 2411.	13.7	11
42	CYP3A5 Genotype Does Not Influence the Blood Concentration of Tacrolimus Measured with the Abbott Immunoassay. Clinical Chemistry, 2005, 51, 2214-2215.	3.2	10
43	Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?. Expert Opinion on Pharmacotherapy, 2005, 6, 2593-2605.	1.8	9
44	Monitoring Immunosuppressive Drugs. Therapeutic Drug Monitoring, 2004, 26, 244-247.	2.0	6
45	Delivering quality for the measurement of immunosuppressive drugs: current performance and future needs. Accreditation and Quality Assurance, 1999, 4, 427-430.	0.8	4
46	An Herbal Remedy for Impotence: More Than Was Bargained For. Journal of Clinical Pharmacology, 2006, 46, 1379-1381.	2.0	4
47	Management of cardiac drug overdose. Resuscitation, 1984, 11, 207-216.	3.0	3
48	Effects of amiodarone on the kinetics of antipyrine. American Journal of Cardiology, 1989, 63, 991-992.	1.6	3
49	Biochemical markers of bone resorption. , 2002, , 122-132.		2
50	Chronic allograft damage index as a surrogate marker for chronic allograft rejection. , 2002, , 433-441.		2
51	Comparison of three infant venous reservoirs with vacuum-assisted venous drainage during varying levels of cardiotomy suction. Perfusion (United Kingdom), 2020, 35, 26-31.	1.0	2
52	Quantification of mycophenolic acid in human plasma by liquid chromatography with timeâ€ofâ€flight mass spectrometry for therapeutic drug monitoring. Biomedical Chromatography, 2021, 35, e5011.	1.7	2
53	Genomics and biomarkers in toxicology. , 2002, , 291-298.		1
54	Evidence-based medicine: evaluation of biomarkers. , 2002, , 3-15.		1

#	Article	IF	Citations
55	Statistical approaches to rational biomarker selection. , 2002, , 24-31.		1
56	Biomarkers of hepatic disease. , 2002, , 167-176.		1
57	Cardiac natriuretic peptides in risk assessment of patients with acute myocardial infarction or congestive heart failure. , 2002, , 334-344.		1
58	Toxicogenetic markers of liver dysfunction. , 2002, , 190-198.		1
59	Biomarkers of bone formation. , 2002, , 115-121.		1
60	Early markers of nephrotoxicity for environmental and occupational monitoring. , 2002, , 66-75.		1
61	Using intelligent systems in clinical decision support. , 2002, , 32-42.		1
62	Bone turnover markers in clinical practice. , 2002, , 99-114.		1
63	Traumatic brain injury: assessment by biochemical serum markers. , 2002, , 398-405.		1
64	Monitoring immunosuppressive drugs. Handbook of Analytical Separations, 2004, , 273-296.	0.8	1
65	Discussion: can upper extremity (deltoid) near infrared spectroscopy be used to assess cerebral tissue bed saturation on femorally cannulated veno-arterial extracorporeal membrane oxygenation patients?. Perfusion (United Kingdom), 2021, 36, 190-199.	1.0	1
66	Colloid Oncotic Pressure, Monitoring its Effects in Cardiac Surgery. Journal of Extra-Corporeal Technology, 2017, 49, 249-256.	0.4	1
67	Proficiency testing schemes for therapeutics and toxicology. Accreditation and Quality Assurance, 2000, 5, 389-391.	0.8	0
68	Sources of preanalytical variability in the measurement of biochemical markers of bone turnover. , 2002, , 140-158.		0
69	Prognosis and management of patients with acute liver failure. , 2002, , 199-210.		0
70	Biomarkers in artificial and bioartificial liver support. , 2002, , 211-220.		0
71	Tumour markers in gastrointestinal disease. , 2002, , 272-280.		0
72	The impact of biochemical tests on patient management. , 2002, , 325-333.		0

#	Article	IF	Citations
73	Monitoring liver transplant recipients. , 2002, , 423-432.		0
74	The early detection of renal impairment in diabetes mellitus. The case for microalbuminuria and other biomarkers. , 2002, , 76-96.		0
75	Genetic approaches to the study of complex diseases: osteoporosis. , 2002, , 159-164.		0
76	IL-6-type cytokines and signalling in inflammation. , 2002, , 256-262.		0
77	Serum markers of inflammation and cardiovascular risk. , 2002, , 345-354.		0
78	An overview of S-100Î² as a clinically useful biomarker of brain tissue damage. , 2002, , 406-412.		0
79	Molecular diagnosis of cytomegalovirus disease. , 2002, , 467-473.		0
80	Development of biomarkers: the industrial perspective. , 2002, , 16-23.		0
81	Biomarkers in renal disease. , 2002, , 45-55.		0
82	Biomarkers for evaluating the safety of genetically modified foods. , 2002, , 313-322.		0
83	Diagnosis and monitoring of inflammatory events in transplant recipients. , 2002, , 474-482.		0
84	The clinical significance of markers of coagulation in acute coronary syndromes. , 2002, , 355-364.		0
85	The clinical application of biomarkers in osteoporosis. , 2002, , 133-139.		0
86	Endothelin: what does it tell us about myocardial and endothelial dysfunction?. , 2002, , 365-373.		0
87	Biomarkers of neurodegenerative disorders. , 2002, , 391-397.		0
88	Homocysteine: a reversible risk factor for coronary heart disease. , 2002, , 374-378.		0
89	Advances in pharmacodynamic biomarkers for monitoring the response to immunosuppressive drug therapy. , 2002, , 442-450.		0
90	The genetics of renal disease. , 2002, , 56-65.		0

#	Article	IF	Citations
91	Prognostic markers in liver disease. , 2002, , 221-227.		0
92	Apoptosis: biomarkers and the key role of mitochondria. , 2002, , 228-238.		0
93	Monitoring heart and lung transplant patients. , 2002, , 415-422.		0
94	Post-transplantation bone disease. , 2002, , 461-466.		0
95	Liver regeneration: mechanisms and markers. , 2002, , 239-243.		0
96	Protein profiling and proteomic databases. , 2002, , 299-312.		0
97	Matrix metalloproteinases and their tissue inhibitors. , 2002, , 379-388.		0
98	The immunogenetics of metabolic liver disease. , 2002, , 177-189.		0
99	Biomarkers in gastrointestinal disease. , 2002, , 265-271.		0
100	The use of biomarkers for monitoring the response to immunosuppressive drug therapy. , 2002, , 451-460.		0
101	Markers of malabsorption: coeliac disease. , 2002, , 281-288.		0
102	Determinants of responses to viruses and self in liver disease. , 2002, , 244-255.		0
103	Practical Applications of Therapeutic Drug Monitoring: The impact of technological developments. , 1989, , 93-102.		0
104	Improving Decreased Heater-Cooler Efficiency as a Result of Heater-Cooler Infection Control Strategy. Journal of Extra-Corporeal Technology, 2019, 51, 73-77.	0.4	0
105	Perfusion Recruitment Strategies Using Choice-Based Conjoint Analysis. Journal of Extra-Corporeal Technology, 2020, 52, 218-226.	0.4	0
106	Alternative Input for Perfusion Management Devices: Voice Recognition for Data Input and the Effects on Charting and Perioperative Calculation Use.. Journal of Extra-Corporeal Technology, 2021, 53, 286-292.	0.4	0